SusanSwindellsMD
Infectious Disease • Omaha, NEProfessor, Internal Medicine, University of Nebraska Medical Center College of Medicine
Are you Dr. Swindells?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 12 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
988102 Nebraska Medical Ctr
Omaha, NE 68198Phone+1 402-559-2666Fax+1 402-559-2677
Summary
- Dr. Susan Swindells, MD is an infectious disease specialist in Omaha, Nebraska. She is currently licensed to practice medicine in Nebraska, Iowa, and Ohio. She is affiliated with Nebraska Medicine - Nebraska Medical Center and is a Professor at University of Nebraska Medical Center College of Medicine.
Education & Training
University of WashingtonResidency, Family Medicine, 1979 - 1980
University of London Faculty of MedicineClass of 1977
Certifications & Licensure
NE State Medical License 1991 - 2026
IA State Medical License 1995 - 2014
OH State Medical License 1988 - 2004
WI State Medical License 1985 - 2001
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Atazanavir/Ritonavir Maintenance Therapy Start of enrollment: 2004 Jul 01
- Observational Study of Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals Start of enrollment: 2009 Dec 01
- Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Start of enrollment: 2010 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Patrick P J Phillips
American Journal of Respiratory and Critical Care Medicine. 2024-12-01 - Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.Renae Furl, Kimberly K Scarsi, Harlan Sayles, Matt Anderson, Joelle Dountio Ofimboudem
Journal of Viral Hepatitis. 2024-11-15 - Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, Gustavo E Velásquez, Payam Nahid
Nature Communications. 2024-10-30
Press Mentions
UNMC for the RecordOctober 8th, 2021- Gilead’s Lenacapavir: HIV Prospects Strongest in Long-Acting Combos with Merck’s IslatravirAugust 25th, 2021
- HIV: Failed Viral Suppression in CAB/RPV Linked to Three Risk FactorsJuly 27th, 2021
- Join now to see all
